NCT05315817TerminatedNot Applicable
Safety and Performance Evaluation of multiPlus Dialysate During CRRT
Fresenius Medical Care Deutschland GmbH1 site in 1 country1 target enrollmentStarted: May 31, 2022Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Enrollment
- 1
- Locations
- 1
- Primary Endpoint
- Serum creatinine removal
Study Overview
Brief Summary
Assessment of the performance of multiPlus dialysate based on the serum creatinine removal 6 hours (360 min) after start of continuous veno-venous haemodialysis/ haemodiafiltration [CVVHD(F)].
multiPlus is a phosphate-containing dialysis solution for the use in continuous renal replacement therapy (CRRT) during acute kidney injury (AKI).
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Signed and dated informed consent form by investigator and by
- •a) the study patient: if patient is able to consent
- •b) the legal representative: if patient is unable to consent:
- •c) an independent consultant: in case of emergency
- •if c) either legal representative or study patient, whichever can be done sooner, should be informed by the investigator as soon as possible. If the informed consent has been obtained by the legal representative (b or emergency scenario) informed consent to continue the participation in the clinical investigation shall be obtained from the subject as soon as he or she is capable of giving informed consent (According to the MDR - Article 68 - Clinical investigations in emergency situations)
- •Minimum age of 18 years
- •Ability to understand the nature and requirements of the study (if patient is conscious)
- •Study specific:
- •Body weight greater than 40 kg
- •Acute Kidney Injury (AKI) with clinical indication for CVVHD/CVVHDF
- •Vascular access allowing blood flow of min 50mL/min
- •Estimated life expectancy greater than 3 days
Exclusion Criteria
- •Any conditions which could interfere with the patient's ability to comply with the study
- •In case of female patients: pregnancy (negative pregnancy test for women below 55 years) or lactation period
- •Participation in an interventional clinical study during the preceding 30 days
- •Previous participation in the same study
- •SARS-CoV 2 positive
- •Study specific
- •Hyperphosphataemia (>4.5 mg/dL)
- •Hypersensitivity to heparin or known history of heparin induced thrombocytopenia (HIT Type II)
- •Uncontrolled bleeding and coagulation disorders
- •Decision to limit therapeutic interventions
- •Advanced malignancy (not including myeloma)
- •Dementia (if definitely not an acute confusional state from uraemia or other acute illness)
- •Advanced cirrhosis with encephalopathy in the absence of possible liver transplantation
Arms & Interventions
multiPlus dialysate
Experimental
Treatment of acute kidney injury patients either with continuous veno-venous haemodialysis (CVVHD) or continuous veno-venous haemodiafiltration (CVVHDF) using the multiPlus dialysate.
Intervention: multiPlus dialysate (Device)
Outcomes
Primary Outcomes
Serum creatinine removal
Time Frame: 360 min after start
The primary variable of this clinical investigation is serum creatinine removal (arterial pre-filter sample taking) assessed 6 hours (360 min) after start of CVVHD(F).
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Terminated
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)Hepatitis C, ChronicNCT01554189Merck Sharp & Dohme LLC37
Unknown
Not Applicable
Intradialytic Creatine SupplementationComplications DialysisNCT05148208University Medical Center Groningen16
Completed
Phase 1
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult ParticipantsHealthy VolunteersNCT06605950Karuna Therapeutics78
Completed
Phase 1
Study of Single and Multiple Doses of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Healthy SubjectsHealthyNCT00709254YM BioSciences12
Completed
Not Applicable
Quality Assessment Creatinines in Plasma and UrineChronic Kidney DiseaseNCT01575392Medical Research Foundation, The Netherlands181